The Salk Institute and BridgeBio Pharma, Inc., announced a three-year collaboration to advance cutting-edge academic discoveries in genetically driven diseases toward therapeutic applications. Under the partnership, BridgeBio will help fund research programs from Salk’s world-renowned innovative cancer research, with the eventual goal of developing new therapeutics for patients in need.

Sign up for our monthly newsletter.

Latest discoveries, events & more.